Trial · NCT01261312
Participant flow208
How many started, completed or left each group, period by period.
1 to 20 of 208
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | 44 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | 35 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | 15 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | STARTED | Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | 44 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | 34 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | 15 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | 0 | |
| Dose Escalation Phase (Day 0- Week 170) | Safety Data Set | Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01261312/flow